| Assessment Status |
Rapid Review Complete |
| HTA ID |
20033 |
| Drug |
Abemaciclib |
| Brand |
Verzenios® |
| Indication |
For the treatment of women with hormone receptor positive , human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. |
| Rapid review commissioned |
06/07/2020 |
| Rapid review completed |
27/08/2020 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of abemaciclib (Verzenios®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
